Navigation Links
Mesa Labs Reports 6% Increase in First Quarter Revenues
Date:8/6/2013

net of tax. A reconciliation between these non-GAAP measures and their GAAP counterparts is set forth in the table below, along with additional information regarding their use.

Financial SummaryStatements of Income(Unaudited)(Amounts in thousands, except per share data)  Three months ended
June 30,20132012Revenues

$ 11,218

$ 10,559Cost of revenues

4,421

4,104  Gross profit

6,797

6,455Operating expenses

3,754

3,236  Operating income

3,043

3,219Other expense, net

28

34  Earnings before income taxes

3,015

3,185Income taxes

1,155

1,086  Net income

$  1,860

$   2,099Net income per share (basic)

$ 0.55

$ 0.63Net income per share (diluted)

0.52

0.59Weighted average common shares outstanding:Basic

3,394

3,337Diluted

3,553

3,541 Balance Sheets(Amounts in thousands)June 30,
2013(Unaudited)March 31,
2013Cash and cash equivalents

$   3,589

$   4,006Other current assets

14,185

15,449  Total current assets

17,774

19,455Property, plant and equipment, net

7,622

7,406Other assets

38,446

39,058  Total assets

$ 63,842$ 65,919Liabilities

$   9,387

$   13,166Stockholders' equity

54,455

52,753  Total liabilities and stockholders' equity

$ 63,842

$ 65,919 Reconciliation of Non-GAAP Measures(Unaudited)(Amounts in thousands, except per share data)Three months ended
June 30,20132012Net income

$ 1,860

$ 2,099Amortization of intangible

  assets, net of tax

 

378

 

383Adjusted net income

$ 2,238

$ 2,482Adjusted net income per sh
'/>"/>

SOURCE Mesa Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. China Biologic Reports Financial Results for the Second Quarter and First Half of 2013
2. BioMed Realty Trust Reports Second Quarter 2013 Financial Results
3. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
4. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
5. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
6. Isis Reports Financial Results and Highlights for Second Quarter 2013
7. CVS Caremark Reports Record Second Quarter Results
8. BioLineRx Reports Second Quarter 2013 Results
9. Regeneron Reports Second Quarter 2013 Financial and Operating Results
10. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
11. Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe ... Italy , UK, Spain ) Summary GBI ... Europe ( Germany , France , ... analysis of the transcatheter heart valves market in Europe . ... period and key company share data by revenue in 2013 for the following ...
(Date:9/23/2014)... -- Report Details Where is the prostate cancer ... potential revenues to 2024, assessing data, trends, opportunities and ... charts, and graphs. Our new study lets you assess ... market, showing their prospects to 2024. Discover the most ... prospects. Our new study lets you assess forecasted sales ...
(Date:9/23/2014)... , Sept. 23, 2014  SI-BONE, Inc., a medical ... Implant System, ® a minimally invasive surgical (MIS) ... today announced that the U.S. Patent and Trademark Office ... and methods for the fixation and fusion of bone.  ... implant with a tapered distal end that may be placed from one ...
Breaking Medicine Technology:Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 3The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 4The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 5SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3
... a biotechnology company that develops targeted therapies for oncology ... results from studies of TRC105 and TRC102 in patients ... Society of Clinical Oncology annual meeting this May 28th ... pathways with the potential for broad application to a ...
... Confirm Tapentadol Efficacy and Tolerability for Acute Pain PatientsRARITAN, ... to 30 percent of all people who have surgery ... The use of opioid pain medicines during and after ... side effects. Nausea and vomiting are uncomfortable and bothersome ...
Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 3New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 4New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 5New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 6New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 7New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 8
(Date:9/23/2014)... Kathleen Doheny HealthDay ... For babies born at very low birth weights, breast milk ... a potentially dangerous infection known as cytomegalovirus (CMV), a new ... low birth weight infants -- all of whom weighed 3.3 ... with a history of CMV infection, to see whether breast ...
(Date:9/23/2014)... News) -- A test used to diagnose lung cancer may ... infections are more common, a new analysis says. ... use of what,s known as functional imaging. For lung cancer, ... according to the study authors. Cancerous tumors generally look ... the lungs that don,t have cancer, according to background information ...
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
(Date:9/23/2014)... 2014 What information do patients ... Quality Forum (NQF) released a report ( http://bit.ly/1DwekE9 ... an infographic ( http://bit.ly/1tX3lzA ) resulting from an ... how patients define affordability, and what information and ... best possible healthcare at the lowest possible cost. ...
(Date:9/23/2014)... New York, NY (PRWEB) September 23, 2014 ... progressive congregation on Manhattan’s Upper West Side that ... will host Inhabiting Eden: Christians, Scripture and the ... K. Tull, A. B. Rhodes Professor Emerita of ... explore the Bible for ancient wisdom that lends ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2
... month long fund raising events to find the cure, ... officially declared November as Tay-Sachs Awareness Month,and encourages all ... the need for research to help find a cure. ... frequently in Ashkenazi Jews, French,Canadians, Louisiana Cajuns, and Irish ...
... breakdown, in the epidermis , , FRIDAY, Nov. 2 (Health ... the biological mechanism by which stress increases susceptibility to ... the basis of the stress," said study author Dr. ... of California, San Francisco, and the VA Medical Center, ...
... Mammography Van Features ... NovationDR Digital System, MALVERN, Pa., Nov. 2 ... digital mammography,system in the U.S. The MAMMOMAT(R) NovationDR, a ... Nevada Cancer Institute,s,(NVCI) new Hope Coach, a mobile digital ...
... Emotional Intelligence could be defined as the capacity to perceive, ... so as to be able to distinguish between emotions and ... actions. One of the important benefits of developing this type ... with others and to face an ever changing social and ...
... LAUREL, N.J., Nov. 2 MedQuist Inc. (Pink,Sheets: MEDQ) ... its,previously-disclosed review of strategic alternatives for the Company, is,evaluating ... best interests of the,Company and its shareholders, in light ... ("Philips") of its decision to proceed,with the sale of ...
... Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today ... designation awarded to PI-88 for the,prevention of tumour ... in order to commence the Phase 3 program ... continue with the Special Protocol,Assessment process. The ...
Cached Medicine News:Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 2Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 3Health News:Stress Robs Skin of Antimicrobial Defenses 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 3Health News:Emotional Intelligence and the use of tobacco and cannabis 2Health News:MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: